WASHINGTON-Facing Congressional criticism that it isn't doing enough to prevent counterfeit-drug imports, the Food and Drug Administration (FDA) is reviewing thousands of drug shipments from foreign countries. The FDA will be examining the drugs to see if counterfeit ingredients have made their way into US drug-making plants. Congressional concerns stem from the potential of substandard ingredients, manufactured in foreign drug plants, being used by the nation's drug makers. The FDA, while often not inspecting these drugs, says it has no evidence of a substantial problem, nor does it believe that the public is at any risk of harm from such substances. Also part of the investigation is increased enforcement and warnings to importers to help regulators keep track of shipments. For more information, visit www.fda.gov.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.